Gabapentin synergistically interacts with topiramate in the mouse maximal electroshock seizure model: An isobolographic analysis

Pharmacological Reports

Volumn 58, Issue 6, 2006, Pages 944-954

  Łuszczki, Jarogniew J ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Gabapentin; Isobolographic analysis; Maximal electroshock; Pharmacodynamic interaction; Topiramate

Indexed keywords

GABAPENTIN; POLYSORBATE 80; SODIUM CHLORIDE; TOPIRAMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG POTENTIATION; ELECTRIC SHOCK; FOCAL EPILEPSY; GRIP STRENGTH; MALE; MOTOR PERFORMANCE; MOUSE; MUSCLE TONE; NONHUMAN; PROVOCATION TEST; SINGLE DRUG DOSE;

EID: 33846322231     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Angehagen M, Ben-Menachem E, Shank R, Ronnback L, Hansson E: Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J Neurochem, 2004, 88, 320-325.
2. Berenbaum MC: What is synergy? Pharmacol Rev 1989, 41, 93-141. Erratum published in Pharmacol Rev, 1990, 41, 422.
3. Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, Schwabe S: Pharmacokinetic interactions of topiramate. Clin Pharmacokinet, 2004, 43, 763-780.
4. Boissier JR, Tardy J, Diverres JC: Une nouvelle methode simple pour explorer l'action «tranquilisante»: le test de la cheminee. Med Exp (Basel), 1960, 3, 81-84.
5. Borowicz KK, Świader M, Łuszczki J, Czuczwar SJ: Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice - an isobolographic analysis. Epilepsia, 2002, 43, 956-963.
6. Brodie MJ, Schachter SC: Fast Facts. Epilepsy, 2nd edn., Health Press, Oxford, 2001.
7. Dalby NO, Nielsen EB: Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. Epilepsy Res, 1997, 28, 63-72.
8. De Sarro G, Gratteri S, Bonacci F, Musumeci SA, Elia M, De Sarro A: Topiramate potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. Eur J Pharmacol, 2000, 388, 163-170.
9. De Sarro G, Spagnolo C, Gareri P, Gallelli L, De Sarro A: Gabapentin potentiates the antiseizure activity of certain anticonvulsants in DBA/2 mice. Eur J Pharmacol, 1998, 349, 179-185.
10. Deckers CLP, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos P et al.: Selection of antiepileptic drug polytherapy based on mechanism of action: the evidence reviewed. Epilepsia, 2000, 41, 1364-1374.
11. Dodgson SJ, Shank RP, Maryanoff BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia, 2000, 41, Suppl 1, S35-S39.
12. Fisher A, Wang X, Cock HR, Thom M, Patsalos PN, Walker MC: Synergism between topiramate and budipine in refractory status epilepticus in the rat. Epilepsia, 2004, 45, 1300-1307.
13. 2δ subunit of calcium channel. J Biol Chem, 1996, 271, 5768-5776.
14. Gibbs JW, Sombati S, DeLorenzo RJ, Coulter DA: Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia, 2000, 41, Suppl 1, S10-S16.
15. Gidal BE: Topiramate. Drug interactions. In: Antiepileptic Drugs, 5th edn. Ed. Levy RH, Mattson RH, Meldrum BS, Perucca E, Lippincott Williams & Wilkins, Philadelphia, 2002, 735-739.
16. Glantz SA, Slinker BK: Primer of applied regression and analysis of variance, 2nd edn. McGraw-Hill Inc., New York, 2001.
17. Goldlust A, Su TZ, Welty DF, Taylor CP, Oxender DL: Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res, 1995, 22, 1-11.
18. Greco WR, Bravo G, Parsons JC: The search for synergy: a critical review from response surface perspective. Pharmacol Rev, 1995, 47, 331-385.
19. Gryder DS, Rogawski MA: Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci, 2003, 23, 7069-7074.
20. Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM: Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology, 2002, 42, 210-220.
21. Jensen AA, Mosbacher J, Elg S, Lingenhoehl K, Lohmann T, Johansen TN, Abrahamsen B et al.: The anticonvulsant gabapentin (neurontin) does not act through gamma-aminobutyric acid-B receptors. Mol Pharmacol, 2002, 61, 1377-1384.
22. Kwan P, Brodie MJ: Early identification of refractory epilepsy. New Eng J Med, 2000, 342, 314-319.
23. Leach JP: Antiepileptic drugs: safety in numbers? Seizure, 2000, 9, 170-178.
24. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
25. Löscher W, Fassbender CP, Nolting B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res, 1991, 8, 79-94.
26. Löscher W, Schmidt D: New horizons in the development of antiepileptic drugs: the search for new targets. Epilepsy Res, 2004, 60, 77-159.
27. Łuszczki JJ, Andres MM, Czuczwar P, Cioczek-Czuczwar A, Ratnaraj N, Patsalos PN, Czuczwar SJ: Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. Epilepsia, 2006, 47, 10-20.
28. Łuszczki JJ, Czuczwar SJ: Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics - a comparative study. Epilepsy Res, 2003, 56, 27-42.
29. Łuszczki JJ, Czuczwar SJ: Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn-Schmiedebergs Arch Pharmacol, 2004, 369, 434-446.
30. Łuszczki JJ, Czuczwar SJ: How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol Rep, 2005, 57, 782-786.
31. Łuszczki JJ, Czuczwar SJ: Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia, 2004, 45, 895-907.
32. Łuszczki JJ, Czuczwar M, Kiś J, Krysa J, Pasztelan I, Świader M, Czuczwar SJ: Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia, 2003, 44, 1003-1013.
33. Łuszczki JJ, Ratnaraj N. Patsalos PN, Czuczwar SJ: Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol, 2006, 373, 169-181.
34. Łuszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ: Pharmacodynamic and pharmacokinetic interaction studies with loreclezole and felbamate, lamotrigine, topiramate and oxcarbazepine in the mouse maximal electroshock seizure model. Epilepsia, 2005, 46, 344-355.
35. Łuszczki JJ, Sacharuk A, Wojciechowska A, Andres-Mach MM, Dudra-Jastrzebska M, Mohamed M, Sawicka KM et al.: 7-Nitroindazole enhances dose-dependently the anticonvulsant activities of conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Pharmacol Rep, 2006, 58, 660-671.
36. Łuszczki JJ, Świader M, Parada-Turska J, Czuczwar SJ: Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsycho-pharmacology, 2003, 28, 1817-1830.
37. Parker DAS, Ong J, Marino V, Kerr DIB: Gabapentin activates presynaptic GABAB heteroreceptors in rat cortical slices. Eur J Pharmacol, 2004, 495, 137-143.
38. Perucca E: Pharmacological principles as a basis for polytherapy. Acta Neurol Scand, 1995, Suppl 162, 31-34.
39. Porreca F, Jiang Q, Tallarida RJ: Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur J Pharmacol, 1990, 179, 463-468.
40. Shank RP, Gardocki IF, Streeter AJ, Maryanoff BE: An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanisms of action. Epilepsia, 2000, 41, Suppl 1, S3-S9.
41. Sills GJ, Butler E, Thompson GG, Brodie MJ: Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. Seizure, 2004, 13, 287-295.
42. Stefani A, Spadoni F, Giacomini P, Lavaroni F, Bernardi G: The effects of gabapentin on different ligand- and voltage-gated currents in isolated cortical neurons. Epilepsy Res, 2001, 43, 239-248.
43. Stephen LJ, Brodie MJ: Seizure-freedom on more than one antiepileptic drug. Seizure, 2002, 11, 349-351.
44. Surges R, Freiman TM, Feuerstein TJ: Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells. Epilepsia, 2003, 44, 150-156.
45. Świader MJ, Łuszczki JJ, Paruszewski R, Czuczwar SJ, Turski WA: Anticonvulsant and acute neurotoxic characteristics of nicotinic acid benzylamide: a preclinical study. Pharmacol Rep, 2006, 58, 431-434.
46. Tallarida RJ: Drug synergism and dose-effect data analysis. Chapman & Hall/CRC, Boca Raton, 2000.
47. + current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther, 1999, 288, 960-968.
48. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ et al.: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res, 1998, 29, 233-249.
49. Vollmer KO, von Hodenberg A, Kölle EU: Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung, 1986, 36, 830-839.
50. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia, 2000, 41, Suppl 1, S17-S20.
51. White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH: Discovery and preclinical development of antiepileptic drugs. In: Antiepileptic Drugs, 5th edn. Ed. Levy RH, Mattson RH, Meldrum BS, Perucca E, Lippincott Williams & Wilkins, Philadelphia, 2002, 36-48.
52. Zhang X, Velumian AA, Jones OT, Carlen PL: Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia, 2000, 41, Suppl 1, S52-S60.